Full-Time

Key Account Manager

Internal Medicine

Updated on 8/23/2026

Deadline 8/28/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$176.6k - $294.3k/yr

+ 20% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Texas, USA

Remote

Relocation assistance may be available based on business needs or eligibility.

Bachelor's, Master's

Category
Sales & Account Management (1)
Required Skills
Sales
Computer Networking
CRM
Financial analysis
Marketing
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • Five to ten years of previous pharmaceutical, biotechnology, medical, marketing, or sales experience is preferred, including at least three years in a promoted position or developmental role demonstrating leadership across peer and manager groups.
  • Candidates must have permanent authorization to work in the United States by any employer.
  • Candidates should demonstrate diverse leadership experience, including the ability to influence and collaborate with peers, develop and coach others, and oversee and guide colleagues' work to achieve meaningful outcomes.
  • Candidates should have knowledge of the healthcare market and disease states, account management and negotiation skills, business planning ability, financial acumen, market and business strategy knowledge, customer management expertise, data analytics and interpretation skills, strategic planning ability, critical and analytical thinking, outcome measurement, relationship management, persuasive oral and written communication, value proposition management, networking, stakeholder management, influencing without authority, compliance commitment, and self-awareness.
Responsibilities
  • Lead the strategic direction, development, and compliant execution of account plans and partnerships with aligned leading health systems and integrated account teams.
  • Develop and manage executive-level customer relationships and align internal and external stakeholders and decision makers to account plans and goals.
  • Identify key customers and the internal and external decision-making and influencing networks affecting key accounts and local health economies.
  • Maintain relationships with customer executives, administrative leaders, decision makers, key opinion leaders, and local health-economy stakeholders.
  • Understand and seek to influence healthcare issues and best practices at the local, regional, and national levels.
  • Manage the co-development and co-execution of project plans while holding the customer and Pfizer accountable for execution.
  • Manage prioritized accounts to achieve agreed business objectives.
  • Identify synergies and collaboration opportunities through active and transparent customer and account planning.
  • Analyze local environments, key-account business models, and Pfizer priorities to create mutually beneficial account plans.
  • Leverage Pfizer's value proposition to create business opportunities that result in action.
  • Connect and communicate stakeholder insights to develop action plans benefiting patients, customers, and Pfizer.
  • Lead and support high-functioning integrated account teams by collaborating with cross-functional specialists and Pfizer stakeholders to align roles, responsibilities, and resources compliantly.
  • Facilitate integrated account team understanding of local market and customer drivers.
  • Influence the development of key account management efforts locally, regionally, and nationally by partnering with cross-functional teams.
  • Share and scale proven practices across the region and nation.
  • Serve as a local expert on healthcare reform, the evolving healthcare landscape, and account and customer organization.
  • Lead strategic planning priorities for aligned key accounts.
  • Use healthcare market knowledge and organizational awareness to involve appropriate colleagues and execute strategic plans addressing issues or solving problems.
  • Lead pull-through activities in alignment with Pfizer business leader direction.
  • Communicate short-, mid-, and long-term Pfizer business views with key accounts and deliver portfolio opportunities across Pfizer business units when appropriate.
  • Provide regional marketing and strategy teams with customer-specific insights to shape strategic direction and market-specific materials.
Desired Qualifications
  • An MBA or advanced degree in a related field is preferred.
  • Management or account management experience is strongly preferred.
  • Ability to develop and manage relationships with key accounts, including C-suite executives, key opinion leaders, and decision makers.
  • Ability to understand, influence, and adapt to changing local healthcare, customer, and stakeholder needs and prioritize resources across accounts.
  • Ability to build and maintain trusting relationships and communicate effectively with audience needs in mind.
  • Ability to provide people development, coaching, and performance management where applicable and adapt positively to challenges and ambiguity.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pfizer raised 2026 revenue guidance to $60.5-$62.5 billion on August 4, 2026.
  • Ex-COVID revenue grew 5% in Q2 2026, driven by Eliquis and Padcev.
  • FDA priority review for Talzenna-Xtandi targets a Q4 2026 approval decision.

What critics are saying

  • Eliquis loses U.S. exclusivity in 2028, threatening Pfizer’s biggest 2026 revenue engine.
  • Paxlovid fell 95% and Comirnaty dropped 34% in Pfizer’s second quarter 2026.
  • If Eliquis replacement and pipeline launches fail, Pfizer becomes a slow-decline cash distributor.

What makes Pfizer unique

  • Pfizer pairs Eliquis scale with oncology assets like Padcev and Talzenna in 2026.
  • Prevnar 20 won Québec public funding in May 2026, deepening vaccine franchise access.
  • Pfizer and Valneva’s Lyme vaccine moved into EMA review on August 14, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
Aug 19th, 2026
Intel CEO invests $10M in shares as chipmaker posts 25% revenue growth driven by AI demand

Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.

Yahoo Finance
Aug 18th, 2026
Two profitable stocks with solid fundamentals and one to ignore

Two companies leverage profitability to outpace competitors, whilst another faces headwinds, according to StockStory's analysis. Primoris, which builds and maintains infrastructure in utility, energy, and civil construction sectors, struggles with a low gross margin of 10.3% reflecting high production costs. The company has seen falling earnings per share over two years and weak free cash flow margin of 2.2% over five years. BrightSpring Health Services, offering home health care and pharmacy services, has posted 23.9% annual revenue growth over two years. Its revenue base of $14.37 billion provides economies of scale. Pfizer's massive $63.7 billion revenue base gives it significant negotiating power. The pharmaceutical giant's adjusted operating margin expanded by 18.5 percentage points over two years, whilst delivering a 17.5% return on capital.

Yahoo Finance
Aug 11th, 2026
Pfizer raises 2026 guidance to $62.5B, but boost relies on Eliquis facing patent expiry

Pfizer reported second-quarter revenue of $15 billion, up 3% year over year, and raised its 2026 revenue guidance to between $60.5 billion and $62.5 billion. However, investors showed limited enthusiasm. The pharmaceutical giant's anticoagulant Eliquis, shared with Bristol Myers Squibb, generated $2.4 billion in quarterly revenue, up 21% year over year. The drug is now Pfizer's best-selling product. The concern is that Eliquis will lose patent exclusivity by the end of the decade. Pfizer's increased reliance on a drug facing imminent generic competition may signal it has yet to identify a suitable replacement. The company is expanding its pipeline, particularly in the GLP-1 market, where its candidate berobenatide is undergoing phase 3 trials after posting strong phase 2 results.

Yahoo Finance
Aug 11th, 2026
Pfizer raises guidance to $62.5B as BioNTech cuts forecast amid $928M loss

Pfizer and BioNTech reported contrasting second-quarter 2026 results as their post-pandemic strategies diverge. While the European Commission authorised their updated COVID-19 vaccine on 29 July, the former partners now face different financial realities. Pfizer posted revenues of $15 billion, up 1% operationally year-over-year. Excluding COVID products, revenue grew 5%, driven by strong performance from Eliquis, Padcev, and other non-COVID products. The company raised full-year revenue guidance by $500 million to $60.5–$62.5 billion and announced productivity initiatives expected to deliver $2.5 billion in additional savings between 2027 and 2029. BioNTech revenues fell 59.5% to €105.6 million as COVID vaccine demand declined. The company reported a net loss of €820.8 million and reduced full-year revenue guidance to €1.6–€1.9 billion. BioNTech maintains €16.6 billion in cash reserves.

Yahoo Finance
Aug 10th, 2026
Pfizer's earnings fall 58%, but dividend appears safe for now

Pfizer reported a 58% decline in net income for the first half of 2024, falling to $2.4 billion from $5.9 billion year-over-year. The decline was largely driven by $3.8 billion in non-cash impairment charges related to in-process research and development assets. Despite the earnings drop, the dividend appears sustainable. Over the past four quarters, Pfizer generated $11 billion in free cash flow, exceeding the approximately $9.8 billion paid in dividends. The company has struggled with growth whilst managing restructuring costs and integrating recent acquisitions. Its second quarter ended 30 June with a $248 million net loss. Pfizer's stock has fallen 44% over five years, though it's up 9% year-to-date. The dividend currently yields 6.4%.